Top Markets
#1 GEKKO GEKKO +53.94%
#2 Helium Helium +53.04%
#3 ADO Protocol ADO Protocol +38.94%
#4 Pons Pons +37.78%
#5 StonkBroker StonkBroker +35.42%
#6 TENDIES TENDIES +31.92%
#7 Prom Prom +29.47%
#8 Collector Crypt Collector Crypt +29.31%
#9 o1.exchange o1.exchange +20.60%
#10 Cysic Cysic +20.33%
Coin of the day
GEKKO GEKKO
Settings
Language
ENGLISH
Currency
USD
Theme
Xvivo Perfusion AB (publ) Xvivo Perfusion AB (publ)

Xvivo Perfusion AB (publ)

XVIVO
Rank in Stocks #9727
Xvivo Perfusion AB (publ) is a medical technology company that creates and... Xvivo Perfusion AB (publ) is a medical technology company that creates and supplies advanced solutions for the preservation and perfusion of organs, tissues, and cells, primarily for use in transplantation. The company's global reach extends across Sweden, the United States, both North and South America, Europe, the Middle East, Africa, and the Asia Pacific region. Its product line includes the XVIVO System (XPS), an integrated, ready-to-use cardiac bypass system designed to facilitate safe normothermic ex vivo lung perfusion (EVLP). To support this, the XPS Disposable Lung Kit offers all the necessary sterile, pre-packed components for EVLP procedures. Xvivo also provides STEEN Solution, an optimally formulated buffered extracellular solution specifically for perfusing isolated donor lungs during EVLP. Additional offerings comprise Perfadex Plus, an extracellular, low-potassium, dextran-based electrolyte preservation solution, and the XVIVO Silicone Tubing Set, used for efficient flushing of donor lungs during the procurement process. The company also manufactures the XVIVO LS and XVIVO Disposable Lung Set, both critical devices for EVLP. Furthermore, Xvivo provides the XVIVO Organ Chamber, a sterile, single-use disposable container for temporarily housing isolated lungs before transplantation, and the XVIVO Lung Cannula Set, another sterile, single-use disposable medical product. Established in 1998, Xvivo Perfusion AB (publ) is headquartered in Gothenburg, Sweden.
Share Price
$30.43
Last synced: 2026-08-28
Market Cap
$958.38M
Change (1 day)
-3.95%
Change (1 year)
71.66%
Country
SE
Trade Xvivo Perfusion AB (publ) (XVIVO)

Category

Healthcare
P/E ratio for Xvivo Perfusion AB (publ) (XVIVO)
P/E ratio as of 2026 TTM: 0
According to Xvivo Perfusion AB (publ) latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Xvivo Perfusion AB (publ) from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Abbott Laboratories Abbott Laboratories
Abbott Laboratories
ABT.US
 35.77 -
US
Stryker Corporation Stryker Corporation
Stryker Corporation
SYK.US
 34.86 -
US
Medtronic plc Medtronic plc
Medtronic plc
MDT.US
 21.39 -
IE
Boston Scientific Corporation Boston Scientific Corporation
Boston Scientific Corporation
BSX.US
 20.90 -
US
Siemens Healthineers AG Siemens Healthineers AG
Siemens Healthineers AG
SHL.DE
 - -
DE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.